CCR7 and neoplasm: We showed that tumor-Ag-specific CD8 T cells at the tumor site, which expressed the ICs PD-1, TIGIT, CTLA-4, and TIM-3, as well as CD39, are at an advanced effector memory (CD45RA-CCR7-) differentiation stage and, for the most part, lose CD28 expression [4].